NASDAQ: DBVTDbv Technologies Sa Stock
$14.47-0.20 (-1.36%)
Updated Aug 18, 2026
DBVT Price
$14.47
Fair Value Price
$2.00
Market Cap
$856.80M
52 Week Low
$8.70
52 Week High
$26.19
P/E
-4.13x
P/B
5.34x
P/S
283.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.02M
Earnings
-$175.99M
Gross Margin
100%
Operating Margin
-3,491.11%
Profit Margin
-3,506.5%
Debt to Equity
0.39
Operating Cash Flow
-$169M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DBVT Overview
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DBVT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DBVT
Ranked#321 of 464
Ranked#321 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $118.10 | A | |
| $6.75 | A |
Be the first to know about important DBVT news, forecast changes, insider trades & much more!
DBVT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DBVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DBVT ($14.47) is overvalued by 624.87% relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DBVT ($14.47) is not significantly undervalued (624.87%) relative to our estimate of its Fair Value price of $2.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DBVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DBVT due diligence checks available for Premium users.
Valuation
DBVT fair value
Fair Value of DBVT stock based on Discounted Cash Flow (DCF)
Price
$14.47
Fair Value
$2.00
Overvalued by
624.87%
DBVT ($14.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DBVT ($14.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DBVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DBVT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.13x
Industry
18.39x
Market
15.03x
DBVT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.34x
Industry
5.4x
DBVT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DBVT's financial health
Profit margin
Revenue
$700.0k
Net Income
-$50.4M
Profit Margin
-7,200%
DBVT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DBVT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$223.2M
Liabilities
$62.8M
Debt to equity
0.39
DBVT's short-term assets ($201.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DBVT's short-term assets ($201.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DBVT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DBVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$52.6M
Investing
-$600.0k
Financing
$100.0k
DBVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DBVT vs Biotech Stocks
Dbv Technologies Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.